A
Altimmune D
D
ALT
4.48000
USD
-0.28
(-5.88%)
قبل الجلسة
حجم التداول
100
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
345,021,188
العنوان: Altimmune
القطاع: Healthcare
الصناعة: Biotechnology
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.